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Wilson’s disease, an autosomal recessive disorder of copper metabolism, is
the most common inherited hepatic disease in Hong Kong. Diagnosis is based
on the presence of Kayser-Fleischer rings, typical neurological symptoms,
and/or a low serum ceruloplasmin concentration (<0.20 g/L). Early detection
and treatment protect patients and their presymptomatic siblings from
devastating organ damage. The diagnosis of Wilson’s disease may nonetheless
be overlooked if only established clinical and laboratory tests are used as
diagnostic criteria. We report diagnosis of the disorder using genetic analysis
of ATP7B in a presymptomatic sibling who escaped diagnosis during family
screening 18 years previously. The patient was 11 months old when family
screening was performed following diagnosis of Wilson’s disease in an elder
sister. The boy was considered to be unaffected on the basis of laboratory
results in the expected range: serum copper level, 4.6 µmol/L; serum
ceruloplasmin level, 0.16 g/L; and 24-hour urinary copper excretion,
0.14 µmol/day. Molecular analysis of ATP7B was performed; it revealed
that the two siblings shared the same compound heterozygous mutations
(G943D and 2299delC). We recommend that molecular diagnosis is the only de-
finitive means of diagnosing Wilson’s disease in children younger than 1 year.
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Introduction
Wilson’s disease (WD) is an autosomal recessive disorder of hepatic copper
metabolism, first described as progressive hepatolenticular degeneration by
Wilson in 1912.1 A detailed pathogenesis of the disorder remains obscure despite
knowledge of its existence for almost a century. Fortunately, clinical phenotypes,
diagnostic biochemical markers, and effective treatment are well established.
Defective copper excretion leads to systemic accumulation of copper that gives
rise to typical phenotypes that include progressive liver damage, neurological
deficits, psychiatric illness, presence of Kayser-Fleischer (KF) rings, renal
tubular disorders, arthropathy, cardiomyopathy, and hypoparathyroidism.2 The
worldwide prevalence has been reported to be approximately 1 in 30 000 with a
carrier rate of 1 in 90. Wilson’s disease is the most common inherited hepatic
disease in Hong Kong. Diagnosis is based on at least two of the following:
detection of KF rings on slit-lamp examination, typical neurological symptoms,
and/or a low serum ceruloplasmin (Cp) concentration (<0.20 g/L). Early detection
and treatment protect patients from devastating organ damage. Timely diagnosis
of WD benefits the patient as well as presymptomatic but affected family
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members, who may be missed if only established clinical
and laboratory tests are used as diagnostic criteria. We
report on a patient in whom the diagnosis was missed for
18 years. Family screening had been previously performed
when the patient was 11 months old. Wilson’s disease was
ultimately diagnosed by genetic testing.
Case report
In 1986, a 4-year-old female (II-1) first presented with
liver impairment associated with generalised malaise and
hepatomegaly. Laboratory investigations revealed a
deranged liver function profile: alanine transaminase
(ALT), 347 U/L; alkaline phosphatase (ALP), 230 U/L; and
total bilirubin, 13 µmol/L. Hepatitis markers were all
negative. Further results demonstrated serum copper was
8.3 µmol/L (reference range, 12-25 µmol/L), serum Cp
0.10 g/L (0.18-0.38 g/L), and 24-hour urinary copper
excretion 2.9 µmol/day (<1.0 µmol/day). Wilson’s disease
was diagnosed and she was prescribed penicillamine.
Family screening for WD was performed in her father (I-3),
mother (I-4), two paternal aunts (I-1 and I-5), an elder
paternal uncle (I-2), and her 11-month-old brother (II-2)
[Fig a]. None of them was thought to be affected. The
patient (II-1) defaulted from further follow-up until 12 years
later in 1998 when she presented in acute hepatic failure
with abdominal distension, jaundice, and hepatomegaly.
No neurological deficit was noted at the time. She was
referred to the Queen Mary Hospital for living-related liver
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Fig. (a) Family pedigree of the reported case. (b) The DNA sequence (in sense direction) of II-2 shows 2299delC (left) and
G943D (right) [arrows]
Cu* and Cp* denote serum copper and ceruloplasmin results reported at the time of II-1 being diagnosed; Cu and Cp serum copper
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(I-1) as donor and made a good recovery. The family was
recruited for genetic analysis of ATP7B in 2002.
Peripheral blood samples were collected from I-1, I-2,
I-3, I-4, I-5, II-1, and II-2 after informed consent was
obtained. Genomic DNA was extracted using a QIAamp
Blood Kit (Qiagen, Hilden, Germany). The coding exons
and the flanking introns of the ATP7B gene were amplified
by polymerase chain reaction (PCR). The PCR products
were sequenced directly by BigDye Terminator cycle
sequencing kit (Applied BioSystems, Foster City, CA, US).
Two known disease-causing mutations of ATP7B
were found in the proband II-1, namely glycine-to-
aspartate substitution at codon 943 (G943D3) and a dele-
tion of cytosine at nucleotide 2299 (2299delC4) [Fig b]. The
younger brother (II-2), now aged 18 years, was also found
to be a compound heterozygote. Serum copper and Cp were
analysed again in view of these results (Fig a).
Discussion
We confirmed the diagnosis of WD using genetic analysis
of ATP7B in an 18-year-old boy, whose diagnosis was
initially missed during previous family screening based
solely on biochemical investigations. Copper homeostasis
is mainly regulated by biliary excretion, and only about 10%
of the absorbed copper is incorporated into Cp that is
secreted into the peripheral circulation. Ceruloplasmin
binds more than 95% of plasma copper and thus protects
peripheral cells from free copper toxicity. It is synthesised
in hepatocytes and secreted into the circulation, with
copper incorporated during transit through the late
secretory pathway. In WD, the defective ATP7B protein
fails in biliary copper excretion and copper incorporation
into apoceruloplasmin (apoCp) which is devoid of copper.
Most apoCp is degraded intracellularly, but moderate
amounts are released into the circulation where apoCp
has a very short half life of a few hours compared with
several days for holoceruloplasmin (holoCp).5 This explains
the significantly reduced serum Cp concentration in WD.
Intriguingly, despite WD being a disorder of copper
overload, total serum copper is reduced as a result of holoCp
deficiency, even though elevated free copper concentrations
lead to unrelenting systemic damage. In our experience, Cp
is the most sensitive biochemical marker for the diagnosis
of WD. Most patients with WD have a serum Cp level of
less than 0.10 g/L. Nevertheless, it is important to realise
that several other factors, including acute hepatic failure
of any cause, nephrotic syndrome and protein-losing
enteropathy, malnutrition,  and hereditary hypo/
aceruloplasminaemia, can influence serum levels. We
should also bear in mind that about 10% of homozygotes
may show normal Cp at the time of diagnosis, especially
during the acute phase of reaction, whereas a similar
percentage of heterozygotes may have reduced levels.
In WD, the serum free copper concentration is elevated.
This fraction is indirectly measured by the non-Cp–bound
serum copper. It is calculated using the formula: total
serum copper (µmol/L) – 47 × serum Cp (g/L).6 An important
assumption of this formula is that all of the serum Cp meas-
ured are holoCp replete of copper. Serum Cp can be meas-
ured by immunochemical or enzymatic activity methods,
expressed in mass unit g/L and in activity unit µmol/L/min,
respectively. Because the former measures both holoCp and
apoCp, immunochemical methods may give higher results.
Therefore, a negative value can be commonly obtained
when serum free copper concentration is calculated using
the immunochemically determined Cp concentration.
However, the validity of this equation has been seriously
challenged and we recommend the direct measurement of
serum-free copper instead.7 On the other hand, some
homozygotes with normal Cp concentration were reported
to have negative Cp oxidase activity revealing the circulat-
ing apoCp.8 Since each Cp carries six copper atoms, their
concentrations are positively correlated provided that holoCp
is measured. Multiplying the Cp result (g/L) by 47 gives its
contribution to serum copper in µmol/L. It is helpful to check
that serum copper and Cp results are compatible with one
another, especially when spurious results are observed, for
example, due to copper contamination and laboratory error.
Age- and sex-specific reference ranges should be
provided to enable accurate interpretation of laboratory
results when the analyte is known to be age- and/or sex-
dependent. Serum Cp concentration is lower in neonates of
25% to 40% of the normal adult level and usually reaches
adult levels by the age of 6 months. It further increases
and reaches its maximum at 2 to 3 years of age, then falls
slowly until the teenage years when adult levels are
finally reached. For patient II-2, the reference ranges
quoted in the previous laboratory report were those for an
adult. If the paediatric reference ranges are applied to the
early results for II-2 (ie serum copper, 3.8-23.8 µmol/L;
serum Cp, 0.15-0.48 g/L in 1 to 12 months old9), the results
(serum copper, 4.6 µmol/L; serum Cp, 0.16 g/L) would
have been within the normal ranges. It is noteworthy that
since the original assay methods are unknown, the reference
ranges quoted here may not apply and are thus just for
general reference. Reference ranges are usually method-
dependent and advice from the manufacturer should be
sought if local data are not available. It should be the
responsibility of the laboratory to provide evidence-based
and valid information on the report to ensure proper
interpretation. A chemical pathologist should be consulted
when there is any doubt. Age-specific reference ranges of
serum copper and Cp are listed in the Table.
Shimizu et al10 have reported the youngest child (8
months old) to be diagnosed with WD detected through
a mass screening system using serum Cp. In contrast to his
greatly decreased serum Cp (0.01 g/L), our case illustrates
that none of the conventional biochemical markers is
reliable in diagnosing WD in paediatric patients, especially
in those under 1 year of age. We speculate that the discrep-
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ancy between the Cp level at 11 months old and at 18 years
old of II-2 may be attributed to the higher production of
apoCp during infancy. Ceruloplasmin oxidase activity
assay may have been able to confirm this reason if it has
been done.
In addition, one should be extremely cautious in
applying the usual diagnostic cut-offs for WD in infancy
when liver function may not be sufficiently mature and
dietary copper content is conceivably much lower than
in a normal adult diet. The latter may also complicate the
interpretation of urinary copper excretion and result in
false-negative results. The results of two 24-hour urinary
copper excretion calculations for II-2 performed at
11 months old were 0.19 µmol/day and 0.14 µmol/day. Care
should be exercised to ensure accurate urine collection,
although this is difficult to achieve in paediatric patients
without a urinary catheter. Furthermore, the moderately
elevated urinary copper may have been due to copper
contamination if ordinary urine bags, which are not copper-
free, were used, or if extraneous copper in tap water was
accidentally added. Presymptomatic patients or
heterozygotes may also demonstrate borderline results;
further investigation is indicated in such cases. A penicilla-
mine challenge test to increase urinary copper excretion
would have been of little diagnostic value in this case, since
the infant body copper is expected to be low and conceiv-
ably it would not give a definitive answer here. We do
not recommend measuring urinary copper excretion in pae-
diatric patients in whom accurate urine collection cannot be
ensured. Measurement of liver copper content was once
advocated as the definitive diagnosis for WD, especially in
young patients with conflicting biochemical patterns. Apart
from being an invasive procedure with inherent risk, up to
500 fold of copper content differences can occur due to sam-
pling error and the heterogeneous distribution of liver
copper.11 We recommend that such an investigative proce-
dure should be discouraged when molecular analysis is
available.
The diagnostic challenges of WD cannot be
overemphasised and the limitations of current clinical
and biochemical tests, especially when performed on the
very young, should be borne in mind. Tests should be
repeated at a later stage if doubt remains. Nevertheless,
diagnosis should be made as early as possible so that an
optimal clinical outcome can be ensured with prophylactic
treatment. Since the total body copper load is expected
to be low in young patients, decoppering agents such as
penicillamine are less preferable because of their adverse
effects. Zinc is safer and lacks the adverse effects on
growth. Marcellini et al12 have demonstrated the excellent
effectiveness of zinc in disease control in a cohort study of
22 paediatric patients with WD spanning 10 years.
Hepatic dysfunction usually precedes neurological
abnormalities in WD. Disease phenotypes and the age of
onset are known to be almost identical among sibling
patients.13 Interestingly, these two siblings who shared
the same mutations presented with two markedly different
phenotypes. Patient II-1 presented with hepatic dysfunction
in her early childhood while II-2 remained fairly asympto-
matic until the teenage years. Mild hand tremors were
noticed only recently. His ALT level was 131 U/L and
ALP level was 134 U/L with normal total bilirubin. It is
postulated that other factors may modulate the clinical
manifestations, for examples ApoE14 and MURR1,15 and
varying dietary copper contents. This possible marked
intra-familial phenotypic variation attests to the importance
of screening by DNA-based testing for family members at
all ages once a proband is diagnosed.
With the advent of molecular biology, it should no longer
be reserved as a research tool. The diagnostic approach is
robust and should be deployed more liberally in clinical
diagnosis, especially where there is already an established
case within the family. The culprit ATP7B gene consists of
21 exons that span a genomic region of about 80 kb and
encode a protein of 1465 amino acids. Mutant ATP7B
results in defective copper incorporation into Cp and a
reduction in biliary copper. To date, 287 mutations have
been reported worldwide.16 Most are missense mutations
and small deletions/insertions. The spectrum of mutations
is population-specific: the most common European
mutation is H1069Q with a frequency of 26% to 70%17 and
(b)
Age-group Serum ceruloplasmin (g/L)
Male Female
Children
QI1-30 d 0.07-0.25 0.03-0.28
QI31-365 d 0.15-0.48 0.15-0.43
QI1-3 y 0.25-0.56 0.29-0.54
QI4-6 y 0.29-0.56 0.26-0.54
QI7-9 y 0.25-0.52 0.23-0.48
QI10-12 y 0.21-0.51 0.21-0.48
QI13-15 y 0.20-0.50 0.21-0.46
QI16-18 y 0.20-0.45 0.22-0.50
Adults (>18 y)
QINo oral contraceptives 0.20-0.40 0.25-0.60
QIWith oral contraceptives - 0.27-0.66
QIor oestrogens
QIPregnant women† - 0.30-1.20
* Reference ranges, which may vary between different methods, are quoted
here for general reference only
† Second and third trimesters; levels increase with gestational age
Table. Age-specific reference ranges* for (a) serum copper
and (b) serum ceruloplasmin5,9
(a)
Age-group Serum copper (µmol/L)
Children
QI0 to <6 m 15.9-16.3
QI6 m to <1 y 13.8-23.8
QI1 to <2 y 11.9-30.3
QI2 to <4 y 13.7-29.3
QI4 to <6 y 18.8-30.0
QI6 to <10 y 18.4-28.4
QI10 to <14 y 13.7-28.5
QI14 to <18 y 11.7-29.3
Adults (≥18 y) 11.0-25.0
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in Asians R778L with a frequency of 28% to 44%.18 Ge-
netic diagnosis confers superior diagnostic specificity and
sensitivity over conventional biochemical tests, especially
for family screening. With proper genetic counselling, simi-
lar tragedies can be prevented or reduced in subsequent gen-
erations with timely diagnosis and therapeutic intervention.
It has been argued that genetic screening is impractical
for WD in view of the many different mutations and the
technical expertise required. While it is generally true
that molecular testing should not be used as a screening
test where there is low clinical suspicion, it remains the most
reliable method of determining the genetic status of
siblings or other relatives when an index case has been
identified.
In conclusion, we have reported on two siblings who
presented with totally different phenotypes despite
harbouring the same mutations (G943D and 2299delC). In
the boy, diagnosis was confirmed after 18 years using ge-
netic analysis of ATP7B.
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